

### RESULTS

#### Results Update

---

##### Century Plyboards (BUY)

Ply disappoints; strong growth in laminates

**Please refer to our website for  
complete coverage universe**

<http://research.ambitcapital.com>

# Century Plyboards

## Ply disappoints; strong growth in laminates

Century Plyboards' revenue was flat YoY (as against 8% revenue growth of its closest peer, Greenply) and EBIT margin dropped 80bps YoY (15.1%), which could be a function of weaker-than-expected industry demand and higher mix of mid-segment products (Sainik). Laminates revenue increased 18% YoY and EBIT margin (16.4%) was its highest ever, which signifies strengthening laminates franchise. Overall EBITDA margin declined 75bps YoY to 16.3% and PAT grew 3% YoY (3% lower than expected). Whilst slowdown in building materials could affect revenue growth in the near-term, we believe that, Century's strong brand, raw material security and product extension (in MDF/particle boards) will help to gain market share from unorganised peers, thereby ensuring growth longevity; working capital cycle would shrink as bargaining power with channel improves (103 days in FY16). Our estimates imply 23%/26% revenue/EBITDA CAGR over FY16-20 (assuming full utilisation of MDF plant); stock trades at 22x FY18E EPS. Our TP implies 26x FY18E EPS.

### Results overview: flat revenues and margin contraction in ply

Century's sales grew by 5% YoY, despite ply revenue remaining flat. Strong growth in laminates (+18% YoY) drove 5% overall growth for the company. Its CFS revenue expanded by 5% YoY. The company's EBITDA margin (ex-forex) declined by 75bps YoY to 16.3% while PAT increased by 3% YoY (ex-forex). Depreciation increased to Rs126mn as against Rs107mn last year. Century's PAT was Rs485mn as against Rs471mn.

**Plyboard segment:** Sales remained flat as against 8% revenue growth posted by Greenply, due to a weaker-than-expected industry growth, higher mix of mid-segment plyboards and lower sales of face veneer. EBIT margin in this segment declined by 77bps YoY, which could be on account of lower margin on face veneer and increasing mix of mid-segment ply. Whilst the management is yet to share the volume details, we believe that volume growth will be in low single digits. The company's particle board unit operated at low utilisation and generated revenues of Rs32mn, implying utilisation rate of ~10%. We believe that poor power availability resulted in low utilisation in this segment.

**Laminates segment:** The segment posted its highest ever revenue (Rs1.04bn; +18% YoY) and EBIT margin (16.4%; +440ps YoY), which is a testament of its growing franchise in this segment. We believe that margin expansion has been led by savings in crude-linked RM costs (40% of overall RM cost for the company) and superior realisation due to improving brand recall post aggressive marketing for the last one year.

**CFS segment:** The segment's revenue grew by 5% YoY, while EBIT margin contracted by 130bps and absolute EBIT remained flat.

**Balance sheet and cash flow statement:** The company's cash conversion cycle shortened to 98 days in 1HFY17 as against 117 days in 1HFY16 and 104 days in FY16. The company generated CFO of ~Rs1bn in 1HFY17. D/E for 1HFY17 was 0.8x (including buyer's credit), similar to the levels as of FY16 year end. Overall debt increased by Rs750mn. The company's gross block increased by Rs600mn (likely on account of commissioning of the particle board plant), other assets increased by Rs1,310mn, due to capital advances given for the MDF plant.

### Where do we go from here?

Despite an evident slowdown in building materials space, our preference for Century Plyboards is premised on the company's initiatives, such as scale and channel expansion, continuous improvement in marketing and distribution architecture, and securing long-term availability of raw material. The company has built the largest capacity of face veneer by an Indian player, in Myanmar (32,000 CBM) and Laos (currently 48,000 CBM, likely to double over the next 2-3 years), with low capital intensity (Rs500mn invested in Laos). It has strategically partnered with a local player in Laos for physical infrastructure (barring machinery) and managing production.

# BUY

## Result Update

### Stock Information

Bloomberg Code:	CPBI IN
CMP (Rs):	251
TP (Rs):	282
Mcap (Rs bn/US\$ bn):	56/0.8
3M ADV (Rs mn/US\$ mn):	63.5/1.0

### Stock Performance (%)

	1M	3M	12M	YTD
Absolute	0	9	44	48
Rel. to Sensex	0	10	39	41

Source: Bloomberg, Ambit Capital research

### Ambit Estimates (Rs bn)

	FY16	FY17E	FY18E
Revenues	16.6	18.8	26.0
EBITDA	2.9	3.2	4.5
EPS (Rs)	7.5	8.0	11.1

Source: Bloomberg, Ambit Capital research

### Research Analysts

**Achint Bhagat, CFA**  
 achint.bhagat@ambit.co  
 Tel: +91 22 3043 3178

**Nitin Bhasin**  
 nitin.bhasin@ambit.co  
 Tel: +91 22 3043 3241

## Preparing for the disruption

Rising acceptance of MDF (as seen in Greenply's success) suggests industry will face disruptions. Whilst entry into MDF will raise capital intensity, Century could generate >20% ROEs as the plant hits full utilisation by FY20. After establishing the third-largest franchise in laminates (4.8mn sheets; 20% revenue CAGR over FY10-16), it is extending its brand to panel products like PVC sheets, cement fibre boards and allied products like wooden flooring and doors.

## Full benefits of brand yet to be realised

Century will capture allied benefits of brand as market gets more organised, which will cut WC cycle to 80 days in FY20 from 103 now. Product extensions and market-share gains would drive 24%/26%/27% sales/EBITDA/EPS CAGR over FY16-19E; RoCE to hit 26% by FY20E as MDF plant reaches full utilisation.

Our estimates imply 23%/26%/28% revenue/EBITDA/PAT CAGR and 25-30% RoEs over FY16-20, post full utilisation of the MDF plant. That said, slowdown in the building material sector persists and hence we might re-assess our near-term assumptions once we get further clarity post its conference call.

## Valuation: Multiples will evolve with the franchise

As Century climbs the evolution curve, it will mirror traits of champion building material franchises – sustained growth/margins, improving RoCEs and P/E re-rating. Our TP (Rs282), implies 18x FY19E EPS, assuming quick ramp-up and 20%+ margin of the MDF plant. At 22.0x FY18E EPS, Century's 10% premium to Greenply is justified by superior RoEs (30% vs 20% for Greenply).

## Questions for the management

We urge investors to understand the following from the management in the earnings conference call:

- **Growth in plyboards:** After a strong volume growth in 1QFY17, the company's volume growth in plyboards has tapered off in 2Q. What led to this? Why is the company unable to gain market share from the unorganised manufacturers?
- **Raw material:** The company has set up a large face veneer capacity in Laos and it is also contemplating expansions in Indonesia. How is this business progressing and is the company committing further capital in expanding its face veneer capacities? Does the company see the face veneer business as an alternate revenue source or a raw material linkage – what is the long-term plan here? Is there a likelihood of disruption in raw material sources, such as Myanmar and Laos and the company's strategy to combat that? We also hear that face veneer despatches from Myanmar were affected in 1QFY17 due to regulatory headwinds, what is the progress on that?
- **Particle board:** How soon can the company reach full utilisation in its particle board business? Can the company post revenues in line with management's initial estimates (Rs800-1,000mn annual revenues)? The company seems to be struggling to ramp-up utilisation here.
- **Laminates business:** The growth in the laminates business was significantly stronger than previous quarters. What was the reason behind this? Is it sustainable? Now with the company nearing full utilisation in laminates, is it planning a capacity expansion?
- **Margin compression:** What has resulted in low EBIT margin for plyboards for the third consecutive quarter? Has the margin on face veneer sales reduced materially?
- **Forex exposure:** What is the current forex exposure of the company and what is the unhedged buyers credit? Why is the company not hedging its forex exposure, despite volatile INR?
- **Capex and funding:** The company has a large capex commitment in the next two years (Rs4.5-5bn), how does it plan to fund it, especially given that internal accruals might remain weak if demand weakness persists? Is the company looking to add capacities in the laminates business as well?

**Exhibit 1: Quarterly summary**

Particulars (Rs mn unless mentioned)	2QFY16	1QFY17	2QFY17	YoY (%)	QoQ (%)	Ambit Est	Dev (%)
Net Sales	4,391	4,036	4,593	4.6	13.8	4,843	(5.2)
Operating costs	3,683	3,374	3,870	5.1	14.7	4,038	(4.2)
EBITDA	739	683	757	2.5	10.8	825	(8.2)
EBITDA margin	16.8	16.9	16.5	-34 bps	-45 bps	17.0	-55 bps
EBITDA (ex-forex)	748	661	748	0.1	13.1	825	(9.3)
EBITDA margin (ex-forex)	17.0	16.4	16.3	-74 bps	-9 bps	17.0	-74 bps
Other income	5	8	13	166.3	63.5	10	31.4
Depreciation	107	93	126	17.5	36.4	120	5.2
EBIT	636	599	622	(2.2)	3.9	715	(13.0)
Interest cost	135	89	60	(55.3)	(32.1)	100	(39.7)
PBT	501	510	584	16.4	14.4	625	(6.6)
Tax	39	80	91	135.4	14.0	125	
PAT	463	431	493	6.5	14.5	500	(1.4)
PAT (adjusted for forex gains/losses)	471	412	485	3.0	17.9	500	(2.9)
EPS	2.1	1.9	2.2	6.5	14.5	2	(1.4)

Source: Company, Ambit Capital research

**Exhibit 2: Segmental performance**

Segmental Sales (Rs mn) (Net of excise)	2QFY16	1QFY17	2QFY17	YoY (%)	QoQ (%)
Plyboard	3,199	2,866	3,202	0.1	11.7
Laminates	885	795	1,043	17.9	31.3
CFS	201	234	211	5.0	(9.9)
Others	115	148	113	(1.7)	(23.5)
<b>Segmental EBIT (Rs mn)</b>					
Plyboard	507	436	483	(4.7)	10.6
Laminates	106	118	171	61.5	45.6
CFS	56	79	56	0.2	(28.3)
<b>Segmental EBIT (%)</b>					
Plyboard	15.8	15.2	15.1	-77 bps	-15 bps
Laminates	12.0	14.8	16.4	443 bps	161 bps
CFS	28.0	33.6	26.7	-128 bps	-686 bps
<b>Capital Employed (Rs mn)</b>					
Plyboard	5,277	5,232	7,628	44.5	45.8
Laminates	1,748	1,594	1,549	(11.4)	(2.8)
CFS	558	531	581	4.2	9.5

Source: Company, Ambit Capital research

**Balance Sheet**

Rs mn unless mentioned	FY15	FY16	FY17E	FY18E	FY19E
Share capital	223	223	223	223	223
Reserves and surplus	3,671	5,104	6,571	8,603	11,287
<b>Total Networth</b>	<b>3,894</b>	<b>5,327</b>	<b>6,794</b>	<b>8,826</b>	<b>11,510</b>
Loans	4,677	4,194	6,494	6,744	6,894
<i>Of which Buyers credit</i>	1,500	1,100	800	800	500
Deferred tax liability (net)	(63)	(130)	(130)	(130)	(130)
<b>Sources of funds</b>	<b>8,564</b>	<b>9,481</b>	<b>13,256</b>	<b>15,547</b>	<b>18,391</b>
Net block	2,456	2,627	6,707	8,022	8,095
Investments	4	2	31	31	31
Cash and bank balances	374	389	235	1,462	3,183
Sundry debtors	2,683	2,873	2,757	3,155	3,691
Inventories	3,322	2,975	3,008	3,512	4,197
Loans and advances	1,349	1,523	1,504	1,786	2,171
<b>Total Current Assets</b>	<b>7,819</b>	<b>8,002</b>	<b>7,746</b>	<b>10,157</b>	<b>13,484</b>
Current liabilities and provisions	2,041	2,175	2,254	2,663	3,219
<b>Net current assets</b>	<b>5,777</b>	<b>5,827</b>	<b>5,492</b>	<b>7,494</b>	<b>10,265</b>
<b>Application of funds</b>	<b>8,564</b>	<b>9,481</b>	<b>13,256</b>	<b>15,547</b>	<b>18,391</b>

Source: Company, Ambit Capital research

**Income statement**

Rs mn unless mentioned	FY15	FY16	FY17E	FY18E	FY19E
Revenue	15,884	16,637	18,837	25,990	31,612
<i>Plyboards</i>	12,431	12,796	14,048	16,835	20,700
<i>Laminates</i>	3,213	3,669	4,278	5,127	6,249
MDF	-	-	-	3,159	4,044
<b>Total expenses</b>	<b>13,326</b>	<b>13,749</b>	<b>15,130</b>	<b>18,034</b>	<b>21,866</b>
<b>EBITDA</b>	<b>2,559</b>	<b>2,888</b>	<b>3,241</b>	<b>4,519</b>	<b>5,639</b>
Depreciation	485	484	701	787	847
<b>EBIT</b>	<b>2,251</b>	<b>2,462</b>	<b>2,612</b>	<b>3,840</b>	<b>4,998</b>
Other income	177	58	72	108	205
<b>Adj PBT</b>	<b>1,796</b>	<b>1,981</b>	<b>2,231</b>	<b>3,207</b>	<b>4,345</b>
Provision for taxation	338	364	446	738	1,086
<b>Adjusted PAT</b>	<b>1,491</b>	<b>1,672</b>	<b>1,776</b>	<b>2,460</b>	<b>3,249</b>
<b>EPS basic (Rs)</b>	<b>6.7</b>	<b>7.5</b>	<b>8.0</b>	<b>11.1</b>	<b>14.6</b>

Source: Company, Ambit Capital research

**Cash flow statement**

<b>Rs mn unless mentioned</b>	<b>FY15</b>	<b>FY16</b>	<b>FY17E</b>	<b>FY18E</b>	<b>FY19E</b>
<b>PBT</b>	<b>1,796</b>	<b>1,981</b>	<b>2,231</b>	<b>3,207</b>	<b>4,345</b>
Depreciation	485	484	701	787	847
Interest paid	456	481	381	632	652
CFO before change in WC	2,701	3,037	3,241	4,519	5,639
Change in working capital	(877)	359	181	(776)	(1,049)
Direct taxes paid	(337)	(468)	(446)	(738)	(1,086)
<b>CFO</b>	<b>1,488</b>	<b>2,928</b>	<b>2,975</b>	<b>3,005</b>	<b>3,504</b>
Net capex	751	1,533	4,781	1,076	920
<b>CFI</b>	<b>128</b>	<b>(1,389)</b>	<b>(4,739)</b>	<b>(968)</b>	<b>(715)</b>
Proceeds from borrowings	(649)	(461)	2,300	250	450
Change in share capital	-	20	-	-	-
Interest & finance charges paid	(335)	(272)	(381)	(632)	(652)
Dividends paid	(462)	(601)	(309)	(428)	(565)
<b>CFF</b>	<b>(1,577)</b>	<b>(1,525)</b>	<b>1,610</b>	<b>(811)</b>	<b>(1,068)</b>
Net increase in cash	39	14	(154)	1,227	1,721
<b>FCF</b>	<b>737</b>	<b>1,395</b>	<b>(1,806)</b>	<b>1,929</b>	<b>2,584</b>

Source: Company, Ambit Capital research

**Ratio analysis / Valuation parameters**

<b>Particulars</b>	<b>FY15</b>	<b>FY16</b>	<b>FY17E</b>	<b>FY18E</b>	<b>FY19E</b>
Revenue growth	17.9	4.7	13.2	38.0	21.6
EBITDA growth	45	13	12	39	25
PAT growth	137	12	6	38	32
EPS norm (dil) growth	90	12	6	39	32
EBITDA margin	16	17	17	17	18
EBIT margin	14	15	14	15	16
Net margin	9	10	9	9	10
RoCE	22	22	18	20	22
RoIC	24	19	22	25	31
RoE	43	36	29	31	32
Working capital turnover	3.0	2.9	3.2	3.3	3.0
Debt/Equity(x)	1.2	0.8	0.9	0.8	0.6
Net debt/Equity(x)	1.1	0.7	0.9	0.6	0.3
<b>Valuation metrics</b>					
P/E (x)	37.4	33.4	28.8	20.8	15.7
P/B(x)	14.1	10.3	7.4	5.7	4.4
EV/Sales(x)	3.8	3.6	3.1	2.6	2.1
EV/EBITDA(x)	23.5	20.6	17.7	12.5	9.7

Source: Company, Ambit Capital research

## Institutional Equities Team

**Saurabh Mukherjea, CFA**      **CEO, Institutional Equities**      **(022) 30433174**      **saurabh.mukherjea@ambit.co**

### Research Analysts

Name	Industry Sectors	Desk-Phone	E-mail
Nitin Bhasin - Head of Research	E&C / Infra / Cement / Industrials	(022) 30433241	nitin.bhasin@ambit.co
Aadesh Mehta, CFA	Banking / Financial Services	(022) 30433239	aadesh.mehta@ambit.co
Abhishek Ranganathan, CFA	Retail	(022) 30433085	abhishek.r@ambit.co
Achint Bhagat, CFA	Cement / Home Building	(022) 30433178	achint.bhagat@ambit.co
Anuj Bansal	Mid-caps	(022) 30433122	anuj.bansal@ambit.co
Aditi Singh	Economy / Strategy	(022) 30433284	aditi.singh@ambit.co
Ashvin Shetty, CFA	Automobile	(022) 30433285	ashvin.shetty@ambit.co
Bhargav Buddhadev	Power Utilities / Capital Goods	(022) 30433252	bhargav.buddhadev@ambit.co
Deepesh Agarwal, CFA	Power Utilities / Capital Goods	(022) 30433275	deepesh.agarwal@ambit.co
Dhiraj Mistry, CFA	Consumer	(022) 30433264	dhiraj.mistry@ambit.co
Gaurav Khandelwal, CFA	Automobile	(022) 30433132	gaurav.khandelwal@ambit.co
Girisha Saraf	Mid-caps / Small-caps	(022) 30433211	girisha.saraf@ambit.co
Karan Khanna, CFA	Strategy	(022) 30433251	karan.khanna@ambit.co
Mayank Porwal	Retail	(022) 30433214	mayank.porwal@ambit.co
Pankaj Agarwal, CFA	Banking / Financial Services	(022) 30433206	pankaj.agarwal@ambit.co
Paresh Dave, CFA	Healthcare	(022) 30433212	paresh.dave@ambit.co
Parita Ashar, CFA	Metals & Mining / Aviation	(022) 30433223	parita.ashar@ambit.co
Prashant Mittal, CFA	Strategy / Derivatives	(022) 30433218	prashant.mittal@ambit.co
Rahil Shah	Banking / Financial Services	(022) 30433217	rahil.shah@ambit.co
Rakshit Ranjan, CFA	Consumer	(022) 30433201	rakshit.ranjan@ambit.co
Ravi Singh	Banking / Financial Services	(022) 30433181	ravi.singh@ambit.co
Ritesh Gupta, CFA	Oil & Gas / Chemicals / Agri Inputs	(022) 30433242	ritesh.gupta@ambit.co
Ritesh Vaidya, CFA	Consumer	(022) 30433246	ritesh.vaidya@ambit.co
Ritika Mankar Mukherjee, CFA	Economy / Strategy	(022) 30433175	ritika.mankar@ambit.co
Ritu Modi	Automobile	(022) 30433292	ritu.modi@ambit.co
Sagar Rastogi	Technology	(022) 30433291	sagar.rastogi@ambit.co
Sudheer Guntupalli	Technology	(022) 30433203	sudheer.guntupalli@ambit.co
Sumit Shekhar	Economy / Strategy	(022) 30433229	sumit.shekhar@ambit.co
Utsav Mehta, CFA	E&C / Industrials	(022) 30433209	utsav.mehta@ambit.co
Vivekanand Subbaraman, CFA	Media	(022) 30433261	vivekanand.s@ambit.co

### Sales

Name	Regions	Desk-Phone	E-mail
Sarojini Ramachandran - Head of Sales	UK	+44 (0) 20 7886 2740	sarojini.r@ambit.co
Dharmen Shah	India / Asia	(022) 30433289	dharmen.shah@ambit.co
Dipti Mehta	India / USA	(022) 30433053	dipti.mehta@ambit.co
Hitakshi Mehra	India	(022) 30433204	hitakshi.mehra@ambit.co
Krishnan V	India / Asia	(022) 30433295	krishnanv@ambit.co
Nityam Shah, CFA	USA / Europe	(022) 30433259	nityam.shah@ambit.co
Parees Purohit, CFA	UK / USA	(022) 30433169	parees.purohit@ambit.co
Praveena Pattabiraman	India / Asia	(022) 30433268	praveena.pattabiraman@ambit.co
Punitraj Mehra, CFA	India / Asia	(022) 30433198	punitraj.mehra@ambit.co
Shaleen Silori	India	(022) 30433256	shaleen.silori@ambit.co

### Singapore

Pramod Gubbi, CFA – Director	Singapore	+65 8606 6476	pramodgubbi@ambitpte.com
Shashank Abhishek	Singapore	+65 6536 1935	shashankabhishek@ambitpte.com

### USA / Canada


Ravilochan Pola - CEO	Americas	+1(646) 361 3107	ravipola@ambitpte.com
-----------------------	----------	------------------	-----------------------

### Production

Sajid Merchant	Production	(022) 30433247	sajid.merchant@ambit.co
Sharoz G Hussain	Production	(022) 30433183	sharoz.hussain@ambit.co
Jestin George	Editor	(022) 30433272	jestin.george@ambit.co
Richard Mugutmal	Editor	(022) 30433273	richard.mugutmal@ambit.co
Nikhil Pillai	Database	(022) 30433265	nikhil.pillai@ambit.co

**Century Plyboards India Ltd (CPBI IN, BUY)**

---



---

Source: Bloomberg, Ambit Capital research



**Explanation of Investment Rating**

Investment Rating	Expected return (over 12-month)
BUY	> 10%
SELL	≤ 10%
NO STANCE	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NOT RATED	We do not have any forward looking estimates, valuation or recommendation for the stock
POSITIVE	We have a positive view on the sector and most of stocks under our coverage in the sector are BUYS
NEGATIVE	We have a negative view on the sector and most of stocks under our coverage in the sector are SELLS

**Disclaimer**

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Ambit Capital. AMBIT Capital Research is disseminated and available primarily electronically, and, in some cases, in printed form.

**Additional information on recommended securities is available on request.**

**Disclaimer**

1. AMBIT Capital Private Limited ("AMBIT Capital") and its affiliates are a full service, integrated investment banking, investment advisory and brokerage group. AMBIT Capital is a Stock Broker, Portfolio Manager and Depository Participant registered with Securities and Exchange Board of India Limited (SEBI) and is regulated by SEBI
2. AMBIT Capital makes best endeavours to ensure that the research analyst(s) use current, reliable, comprehensive information and obtain such information from sources which the analyst(s) believes to be reliable. However, such information has not been independently verified by AMBIT Capital and/or the analyst(s) and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. AMBIT Capital may or may not subscribe to any and/ or all the views expressed herein.
3. This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report and AMBIT Capital or its affiliates shall not be responsible and/ or liable for any direct/consequential loss howsoever directly or indirectly, from any use of this Research Report.
4. If this Research Report is received by any client of AMBIT Capital or its affiliate, the relationship of AMBIT Capital/its affiliate with such client will continue to be governed by the terms and conditions in place between AMBIT Capital/ such affiliate and the client.
5. This Research Report is issued for information only and the 'Buy', 'Sell', or 'Other Recommendation' made in this Research Report such should not be construed as an investment advice to any recipient to acquire, subscribe, purchase, sell, dispose of, retain any securities and should not be intended or treated as a substitute for necessary review or validation or any professional advice. Recipients should consider this Research Report as only a single factor in making any investment decisions. This Research Report is not an offer to sell or the solicitation of an offer to purchase or subscribe for any investment or as an official endorsement of any investment.
6. This Research Report is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied in whole or in part, for any purpose. Neither this Research Report nor any copy of it may be taken or transmitted or distributed, directly or indirectly within India or into any other country including United States (to US Persons), Canada or Japan or to any resident thereof. The distribution of this Research Report in other jurisdictions may be strictly restricted and/ or prohibited by law or contract, and persons into whose possession this Research Report comes should inform themselves about such restriction and/ or prohibition, and observe any such restrictions and/ or prohibition.
7. Ambit Capital Private Limited is registered as a Research Entity under the SEBI (Research Analysts) Regulations, 2014. SEBI Reg.No.- INH000000313.

**Conflict of Interests**

8. In the normal course of AMBIT Capital's business circumstances may arise that could result in the interests of AMBIT Capital conflicting with the interests of clients or one client's interests conflicting with the interest of another client. AMBIT Capital makes best efforts to ensure that conflicts are identified and managed and that clients' interests are protected. AMBIT Capital has policies and procedures in place to control the flow and use of non-public, price sensitive information and employees' personal account trading. Where appropriate and reasonably achievable, AMBIT Capital segregates the activities of staff working in areas where conflicts of interest may arise. However, clients/potential clients of AMBIT Capital should be aware of these possible conflicts of interests and should make informed decisions in relation to AMBIT Capital's services.
9. AMBIT Capital and/or its affiliates may from time to time have or solicit investment banking, investment advisory and other business relationships with companies covered in this Research Report and may receive compensation for the same.

**Additional Disclaimer for U.S. Persons**

10. The research report is solely a product of AMBIT Capital
11. AMBIT Capital is the employer of the research analyst(s) who has prepared the research report
12. Any subsequent transactions in securities discussed in the research reports should be effected through Enclave Capital LLC. ("Enclave").
13. Enclave does not accept or receive any compensation of any kind for the dissemination of the AMBIT Capital research reports.
14. The research analyst(s) preparing the email / Research Report/ attachment is resident outside the United States and is/are not associated persons of any U.S. regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.
15. This report is prepared, approved, published and distributed by the Ambit Capital located outside of the United States (a non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of Ambit Capital only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036). In order to receive any additional information about or to effect a transaction in any security or financial instrument mentioned herein, please contact a registered representative of Enclave Capital LLC., by phone at 646 361 3107.
16. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.
17. This document does not constitute an offer of, or an invitation by or on behalf of Ambit Capital or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Ambit Capital or its Affiliates consider to be reliable. None of Ambit Capital accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

**Additional Disclaimer for Canadian Persons**

18. AMBIT Capital is not registered in the Province of Ontario and /or Province of Québec to trade in securities and/or to provide advice with respect to securities.
19. AMBIT Capital's head office or principal place of business is located in India.
20. All or substantially all of AMBIT Capital's assets may be situated outside of Canada.
21. It may be difficult for enforcing legal rights against AMBIT Capital because of the above.
22. Name and address of AMBIT Capital's agent for service of process in the Province of Ontario is: Torsys LLP, 79 Wellington St. W., 30th Floor, Box 270, TD South Tower, Toronto, Ontario M5K 1N2 Canada.
23. Name and address of AMBIT Capital's agent for service of process in the Province of Montréal is Torsys Law Firm LLP, 1 Place Ville Marie, Suite 1919 Montréal, Québec H3B 2C3 Canada.

**Additional Disclaimer for Singapore Persons**

24. This Report is prepared and distributed by Ambit Capital Private Limited and distributed as per the approved arrangement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of the First Schedule to the Financial Advisors Act (CAP 110) provided to Ambit Singapore Pte. Limited by Monetary Authority of Singapore.
25. This Report is only available to persons in Singapore who are institutional investors (as defined in section 4A of the Securities and Futures Act (Cap. 289) of Singapore (the "SFA")." Accordingly, if a Singapore Person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform Ambit Singapore Pte. Limited.

**Additional Disclaimer for UK Persons**

26. All of the recommendations and views about the securities and companies in this report accurately reflect the personal views of the research analyst named on the cover. No part of this research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report. This report may not be reproduced, redistributed or copied in whole or in part for any purpose.
27. This report is a marketing communication and has been prepared by Ambit Capital Pvt Ltd of Mumbai, India ("Ambit") and has been approved in the UK by Ambit Capital (UK) Limited ("ACUK") solely for the purposes of section 21 of the Financial Services and Markets Act 2000. Ambit is regulated by the Securities and Exchange Board of India and is registered as a Research Entity under the SEBI (Research Analysts) Regulations, 2014. ACUK is regulated by the UK Financial Services Authority and has registered office at C/o Panmure Gordon & Co PL, One New Change, London, EC4M9AF.
28. In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are professional customers or eligible counterparties of ACUK (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the UK who are not relevant persons.
29. Neither Ambit nor ACUK is a US registered broker-dealer. Transactions undertaken in the US in any security mentioned herein must be effected through a US-registered broker-dealer, in conformity with SEC Rule 15a-6.
30. Neither this report nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities laws, or the law of any such other jurisdictions.
31. This report does not constitute an offer or solicitation to buy or sell any securities referred to herein. It should not be so construed, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information in this report, or on which this report is based, has been obtained from publicly available sources that Ambit believes to be reliable and accurate. However, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It has also not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties.
32. The information or opinions are provided as at the date of this report and are subject to change without notice. The information and opinions provided in this report take no account of the investors' individual circumstances and should not be taken as specific advice on the merits of any investment decision. Investors should consider this report as only a single factor in making any investment decisions. Further information is available upon request. No member or employee of Ambit or ACUK accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of this report or its contents.
33. The value of any investment made at your discretion based on this Report, or income therefrom, may be affected by changes in economic, financial and/or political factors and may go down as well as go up and you may not get back the original amount invested. Some securities and/or investments involve substantial risk and are not suitable for all investors.
34. Ambit and its affiliates and their respective officers directors and employees may hold positions in any securities mentioned in this Report (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). Ambit and ACUK may from time to time render advisory and other services to companies referred to in this Report and may receive compensation for the same.
35. Ambit and its affiliates may act as a market maker or risk arbitrator or liquidity provider or may have assumed an underwriting commitment in the securities of companies discussed in this Report (or in related investments) or may sell them or buy them from clients on a principal to principal basis or may be involved in proprietary trading and may also perform or seek to perform investment banking or underwriting services for or relating to those companies.
36. Ambit and ACUK may sell or buy any securities or make any investment which may be contrary to or inconsistent with this Report and are not subject to any prohibition on dealing. By accepting this report you agree to be bound by the foregoing limitations. In the normal course of Ambit and its affiliates' business, circumstances may arise that could result in the interests of Ambit conflicting with the interests of clients or one client's interests conflicting with the interest of another client. Ambit makes best efforts to ensure that conflicts are identified, managed and clients' interests are protected. However, clients/potential clients of Ambit should be aware of these possible conflicts of interests and should make informed decisions in relation to Ambit services.

**Disclosures**

37. The analyst (s) has/have not served as an officer, director or employee of the subject company.
38. There is no material disciplinary action that has been taken by any regulatory authority impacting equity research analysis activities.
39. All market data included in this report are dated as at the previous stock market closing day from the date of this report.

**Analyst Certification**

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

© Copyright 2015 AMBIT Capital Private Limited. All rights reserved.